共 171 条
[1]
Alptekin K(2009)Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study Int Clin Psychopharmacol 24 229-238
[2]
Hafez J(2005)Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia Am J Psychiatry 162 1879-1887
[3]
Brook S(2005)Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine Int Clin Psychopharmacol 20 105-112
[4]
Akkaya C(2007)Olanzapine versus chlorpromazine in the treatment of schizophrenia: a pooled analysis of four 6-week, randomized, open-label studies in the Middle East and North Africa J Clin Psychopharmacol 27 329-337
[5]
Tzebelikos E(2007)Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia J Am Pharm Assoc: JAPhA 47 373-378
[6]
Ucok A(1989)High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies Circulation 79 8-15
[7]
El Tallawy H(2011)Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial Schizophr Bull 37 352-361
[8]
Danaci AE(2007)Weight gain with atypical antipsychotics: evidence and insights J clin psychiatry 68 18-26
[9]
Lowe W(1996)Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies J Cardiovasc Risk 3 213-219
[10]
Karayal ON(2009)Systematic review: association of low-density lipoprotein subfractions with cardiovascular outcomes Ann Intern Med 150 474-484